Tsai‐Sheng Yang

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

Medicine, Oncology, Pharmacotherapy +11

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial

Ann‐Lii Cheng, Zhongzhen Guan, Zhendong Chen et al. · European Journal of Cancer · 2012 · 261 citations · Full text

Medicine, Oncology, Pharmacology +13

Mutations of <i>KRAS/NRAS/BRAF</i> predict cetuximab resistance in metastatic colorectal cancer patients

Hung‐Chih Hsu, Tan Kien Thiam, Yen‐Jung Lu et al. · Oncotarget · 2016 · 129 citations · Full text

Medicine, Genetics, Oncology +17

Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study

Chiun Hsu, Tsai‐Sheng Yang, Teh‐Ia Huo et al. · Journal of Hepatology · 2012 · 97 citations

Medicine, Oncology, Pharmacology +14

Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer

Hung‐Chih Hsu, Yi‐Shiuan Liu, Kai-Chi Tseng et al. · International Journal of Colorectal Disease · 2013 · 87 citations

Medicine, Oncology, Pharmacology +13